Primary End-Point! "Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint of the study) in the leronlimab versus placebo." -CytoDyn PR 3/5/21

Boom.

https://tylerpaper.com/ap/business/cytodyn-s-...f58a8.html